LY3471851 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colitis, Ulcerative
Conditions
Colitis, Ulcerative
Trial Timeline
Mar 22, 2021 → Aug 9, 2022
NCT ID
NCT04677179About LY3471851 + Placebo
LY3471851 + Placebo is a phase 2 stage product being developed by Eli Lilly for Colitis, Ulcerative. The current trial status is terminated. This product is registered under clinical trial identifier NCT04677179. Target conditions include Colitis, Ulcerative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04677179 | Phase 2 | Terminated |
| NCT04433585 | Phase 2 | Completed |
| NCT04081350 | Phase 1 | Completed |
| NCT04133116 | Phase 1 | Completed |
| NCT03556007 | Phase 1 | Completed |
| NCT04380324 | Phase 1 | Completed |
Competing Products
20 competing products in Colitis, Ulcerative
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirikizumab SC + Mirikizumab IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 2 | 52 |
| Azathioprine + Placebo | Celltrion | Approved | 85 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + Placebo | Astellas Pharma | Phase 3 | 77 |
| Filgotinib Maleate | Eisai | Approved | 85 |
| AJM300 + Placebo | Eisai | Phase 3 | 77 |
| GSK3050002 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + placebo | Eisai | Phase 3 | 77 |
| E6007 + Placebo | Eisai | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Arm1 + Arm 2 | Zydus Lifesciences | Phase 2 | 52 |
| Mirikizumab + Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4268989 + Placebo | Eli Lilly | Phase 2 | 52 |
| Eltrekibart + Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |